# Study to Investigate the Efficacy and Safety of Mexiletine in Patients With Myotonic Dystrophy Type 1 and Type 2

> **NCT04700046** · PHASE3 · WITHDRAWN · sponsor: **Lupin Ltd.**

## Conditions studied

- Myotonic Dystrophy Type 1 and Type 2

## Interventions

- **DRUG:** Mexiletine 167 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04700046
- **Lead sponsor:** Lupin Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-09-03
- **Primary completion:** 2024-07-01
- **Final completion:** 2024-08-12
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Assessing novel alternative study designs and regulatory pathways
- **Last updated:** 2024-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04700046

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04700046, "Study to Investigate the Efficacy and Safety of Mexiletine in Patients With Myotonic Dystrophy Type 1 and Type 2". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04700046. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*